POS0529 USING SOCIAL MEDIA CONVERSATIONS TO UNDERSTAND PATIENT CARE: FACTORS DRIVING PROACTIVE VS REACTIVE MANAGEMENT OF GOUT

痛风 医学 社会化媒体 子专业 疾病管理 物理疗法 家庭医学 疾病 内科学 计算机科学 万维网 帕金森病
作者
M. Flurie,M. Converse,Karina W. Davidson,Daniel Hernandez,H. Hernandez,G. C. Ho,B. Lamoreaux,Christine Parker,C. DeFelice,Maurice Flurie,E. Robert Wassman
标识
DOI:10.1136/annrheumdis-2023-eular.1625
摘要

Background

To understand the needs of a particular community, it is imperative to actively listen to and interpret the patient experience. We used a proprietary artificial intelligence (AI) analytics engine that uses natural language processing to evaluate social media conversations in online gout communities. Gout is a chronic disease defined by uric acid crystal deposits which induce painful arthritis flares/flare-ups [1]. Managing gout can be characterized by two approaches: proactive and reactive management. Proactive management refers to scheduled, prophylactic care (e.g., regular doctor visits, treating underlying illness), whereas reactive management is spontaneous care driven by symptom onset (e.g., urgent care/walk-in clinic visits). The ideal management strategy is debated. Subspecialty groups recommend a proactive “treat-to-target” strategy focused on uric acid. The American College of Physicians recommends “treat-to-symptom control” without a “treat-to-uric acid-target” strategy. We assessed patient views on each to improve our understanding of these management methods.

Objectives

The current study aimed to identify gout symptoms associated with reactive management. We also wanted to contrast the sentiment of online gout community conversations when describing proactive vs reactive therapeutic experiences.

Methods

We evaluated 2 social media sources: a private Facebook group, The Gout Support Group of America (1000+ members, 99 countries), which had 50,000 posts/comments gathered in 2021-2022; and a public subreddit (r/gout) (9000+ members) with 125,000 posts/comments from 2011-2022. Our AI engine first tagged all posts/comments discussing proactive or reactive care experiences. Entity recognition was then used to identify the most frequently mentioned clinical findings in conversations by care type. We then fit a logistic regression model in which clinical finding mentions predicted care type. To characterize the general sentiment of conversations, the engine scored all posts/comments from −1 (most negative) to 1 (most positive) using a pretrained sentiment tagger.

Results

Flares, pain, uric acid, and swelling were the most frequently mentioned in both proactive and reactive conversations. Reactive care gout conversations (n = 1253 posts/comments from 624 users) were associated with a significantly higher probability of mentioning ‘pain’ and ‘swelling’ and a significantly lower probability of mentioning ‘uric acid’ than were proactive care conversations (n = 1205 posts/comments, 521 users). Mentioning ‘flares’ did not significantly impact the probability of mentioning either care type. Sentiment analysis showed that reactive care statements had a significantly lower mean sentiment score; indicating discussions about reactive care experiences tended to be more negative than those about proactive care.

Conclusion

In analyzing gout social media posts, we found that flares, pain, swelling, and concerns related to uric acid were primary motivators for individuals seeking gout care. Conversations mentioning ‘pain’ were twice as likely to mention reactive care compared to proactive gout conversations. Analysis also showed that reactive care gout conversations tended to be more negative, supporting the position that proactive management may be more beneficial for individuals with gout overall. This type of information can be used to identify and address patients’ areas of concern or dissatisfaction. Future work should continue exploring these patient-reported perspectives and experiences so clinicians, caregivers, and patients can better understand and guide care-based management decisions.

References

[1]Mikuls TR. Gout. N Engl J Med. 2022;387(20):1877-1887. doi:10.1056/NEJMcp2203385

Acknowledgements

The authors would like to thank our TREND Community managers Matthew Horsnell and Rachelle Cook for their contribution in providing advocacy and support for the gout community; and the private Facebook group, Gout Support Group of America, for providing access to data during the preparation of this abstract. Funding for this work was provided by Horizon Therapeutics.

Disclosure of Interests

Maurice Flurie Grant/research support from: Our clients are pharmaceutical and biotechnology companies including, but not limited to Horizon Therapeutics, Chiesi Global Rare Disease, Novartis, Harmony Biosciences, and Avadel. TREND Community: employee, Monica Converse Grant/research support from: Our clients are pharmaceutical and biotechnology companies including, but not limited to Horizon Therapeutics, Chiesi Global Rare Disease, Novartis, Harmony Biosciences, and Avadel. TREND Community: employee, Kristina Davidson Shareholder of: Horizon Therapeutics, Employee of: Horizon Therapeutics, Daniel Hernandez: None declared, Helen Hernandez: None declared, Gary Ho Grant/research support from: Horizon Therapeutics, Brian LaMoreaux Shareholder of: Horizon Therapeutics, Employee of: Horizon Therapeutics, Christopher Parker Speakers bureau: Horizon Therapeutics, Christopher DeFelice Grant/research support from: Our clients are pharmaceutical and biotechnology companies including, but not limited to Horizon Therapeutics, Chiesi Global Rare Disease, Novartis, Harmony Biosciences, and Avadel. TREND Community: owner, Maria Picone Grant/research support from: Our clients are pharmaceutical and biotechnology companies including, but not limited to Horizon Therapeutics, Chiesi Global Rare Disease, Novartis, Harmony Biosciences, and Avadel. TREND Community: owner, E. Robert Wassman Grant/research support from: Our clients are pharmaceutical and biotechnology companies including, but not limited to Horizon Therapeutics, Chiesi Global Rare Disease, Novartis, Harmony Biosciences, and Avadel. TREND Community: employee.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
n11发布了新的文献求助10
刚刚
fann发布了新的文献求助30
刚刚
小蘑菇的应助被神勇绮烟采纳,获得10
刚刚
111完成签到,获得积分10
刚刚
小臣发布了新的文献求助10
刚刚
薏仁做事薏仁汤完成签到,获得积分10
刚刚
时间9完成签到,获得积分10
刚刚
denisewang发布了新的文献求助10
1秒前
山风发布了新的文献求助10
1秒前
小李完成签到 ,获得积分20
1秒前
1秒前
木木发布了新的文献求助10
2秒前
jinzhou完成签到,获得积分10
3秒前
方方发布了新的文献求助20
3秒前
luoluoan发布了新的文献求助30
3秒前
高兴的初夏完成签到,获得积分10
3秒前
3秒前
4秒前
4秒前
ZnGaLi发布了新的文献求助20
4秒前
5秒前
orixero的应助被hjygzv采纳,获得10
5秒前
什米完成签到,获得积分10
5秒前
5秒前
范梦丽发布了新的文献求助10
5秒前
5秒前
失眠代秋完成签到 ,获得积分10
6秒前
Zz发布了新的文献求助10
6秒前
Regn完成签到,获得积分10
6秒前
李健的应助被yi采纳,获得10
6秒前
zhoujin完成签到,获得积分20
6秒前
7秒前
7秒前
7秒前
7秒前
汉堡包的应助被九月初采纳,获得10
7秒前
安详晓亦发布了新的文献求助10
8秒前
liujiaqi完成签到,获得积分10
8秒前
谦让秋白完成签到,获得积分10
8秒前
8秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Improving the wear resistance of vehicle gear oil by oil soluble LaF3 nanoparticles and typical additives of gear oil 500
Boundaries and Bodhisattvas 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8183046
求助须知:如何正确求助?哪些是违规求助? 9572370
关于积分的说明 21824411
捐赠科研通 7779694
什么是DOI,文献DOI怎么找? 3433792
关于科研通互助平台的介绍 2558024
邀请新用户注册赠送积分活动 2479971